Amedisys, Inc. (NASDAQ:AMED) Sees Significant Increase in Short Interest

Key Points

Error: Response status code does not indicate success: 429 (Too Many Requests).

Amedisys, Inc. (NASDAQ:AMED - Get Free Report) saw a significant increase in short interest in July. As of July 31st, there was short interest totaling 3,200,000 shares, anincreaseof42.9% from the July 15th total of 2,240,000 shares. Based on an average daily trading volume, of 482,600 shares, the short-interest ratio is currently 6.6 days. Currently,10.0% of the shares of the stock are short sold. Currently,10.0% of the shares of the stock are short sold. Based on an average daily trading volume, of 482,600 shares, the short-interest ratio is currently 6.6 days.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the company. Allworth Financial LP increased its stake in Amedisys by 155.8% in the second quarter. Allworth Financial LP now owns 289 shares of the health services provider's stock valued at $28,000 after acquiring an additional 176 shares during the last quarter. Hexagon Capital Partners LLC increased its stake in Amedisys by 108.1% in the first quarter. Hexagon Capital Partners LLC now owns 310 shares of the health services provider's stock valued at $29,000 after acquiring an additional 161 shares during the last quarter. Caitong International Asset Management Co. Ltd bought a new position in Amedisys in the second quarter valued at approximately $32,000. MassMutual Private Wealth & Trust FSB increased its stake in Amedisys by 56.1% in the first quarter. MassMutual Private Wealth & Trust FSB now owns 334 shares of the health services provider's stock valued at $31,000 after acquiring an additional 120 shares during the last quarter. Finally, Fifth Third Bancorp increased its stake in Amedisys by 68.1% in the first quarter. Fifth Third Bancorp now owns 348 shares of the health services provider's stock valued at $32,000 after acquiring an additional 141 shares during the last quarter. 94.36% of the stock is owned by institutional investors.

Amedisys Stock Up 0.0%

NASDAQ AMED opened at $101.01 on Tuesday. The company has a current ratio of 1.36, a quick ratio of 1.36 and a debt-to-equity ratio of 0.26. Amedisys has a 1-year low of $82.15 and a 1-year high of $101.02. The company has a 50 day moving average of $98.15 and a 200-day moving average of $94.82. The company has a market cap of $3.32 billion, a price-to-earnings ratio of 39.30, a PEG ratio of 1.34 and a beta of 0.89.

Amedisys (NASDAQ:AMED - Get Free Report) last released its quarterly earnings results on Tuesday, July 29th. The health services provider reported $1.54 earnings per share for the quarter, beating analysts' consensus estimates of $1.39 by $0.15. Amedisys had a net margin of 3.56% and a return on equity of 12.91%. The company had revenue of $621.86 million during the quarter, compared to the consensus estimate of $614.61 million. During the same period in the previous year, the business earned $0.98 earnings per share. The firm's quarterly revenue was up 5.2% on a year-over-year basis. On average, equities research analysts expect that Amedisys will post 4.4 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Separately, Wall Street Zen downgraded shares of Amedisys from a "strong-buy" rating to a "buy" rating in a research report on Saturday, May 24th.

About Amedisys

Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; nursing services, rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.